company background image
MYX

Mayne Pharma GroupASX:MYX Stock Report

Market Cap

AU$582.4m

7D

-1.5%

1Y

6.5%

Updated

26 Oct, 2021

Data

Company Financials +
MYX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends0/6

MYX Overview

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Asia, and internationally.

Mayne Pharma Group Competitors

Roche Holding

SWX:ROG

CHF311.4b

AstraZeneca

LSE:AZN

UK£138.5b

Novartis

SWX:NOVN

CHF174.2b

Sanofi

ENXTPA:SAN

€107.5b

Price History & Performance

Summary of all time highs, changes and price drops for Mayne Pharma Group
Historical stock prices
Current Share PriceAU$0.33
52 Week HighAU$0.26
52 Week LowAU$0.59
Beta0.91
1 Month Change10.00%
3 Month Change4.76%
1 Year Change6.45%
3 Year Change-70.54%
5 Year Change-79.11%
Change since IPO-45.00%

Recent News & Updates

Shareholder Returns

MYXAU PharmaceuticalsAU Market
7D-1.5%-1.0%0.8%
1Y6.5%8.7%24.4%

Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned 8.7% over the past year.

Return vs Market: MYX underperformed the Australian Market which returned 24.4% over the past year.

Price Volatility

Is MYX's price volatile compared to industry and market?
MYX volatility
MYX Beta0.91
Industry Beta1.3
Market Beta1

Stable Share Price: MYX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MYX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005n/aScott Richardshttps://www.maynepharma.com

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Asia, and internationally. The company operates through four segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.

Mayne Pharma Group Fundamentals Summary

How do Mayne Pharma Group's earnings and revenue compare to its market cap?
MYX fundamental statistics
Market CapAU$582.40m
Earnings (TTM)-AU$208.42m
Revenue (TTM)AU$400.78m

1.5x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MYX income statement (TTM)
RevenueAU$400.78m
Cost of RevenueAU$218.80m
Gross ProfitAU$181.98m
ExpensesAU$390.40m
Earnings-AU$208.42m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.12
Gross Margin45.41%
Net Profit Margin-52.00%
Debt/Equity Ratio43.8%

How did MYX perform over the long term?

See historical performance and comparison

Valuation

Is Mayne Pharma Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MYX (A$0.33) is trading below our estimate of fair value (A$3.48)

Significantly Below Fair Value: MYX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MYX is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: MYX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYX is good value based on its PB Ratio (0.8x) compared to the AU Pharmaceuticals industry average (3.7x).


Future Growth

How is Mayne Pharma Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

112.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: MYX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MYX's is expected to become profitable in the next 3 years.

Revenue vs Market: MYX's revenue (16.3% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: MYX's revenue (16.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MYX's Return on Equity is forecast to be low in 3 years time (10.1%).


Past Performance

How has Mayne Pharma Group performed over the past 5 years?

-46.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYX is currently unprofitable.

Growing Profit Margin: MYX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYX is unprofitable, and losses have increased over the past 5 years at a rate of 46.1% per year.

Accelerating Growth: Unable to compare MYX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: MYX has a negative Return on Equity (-27.1%), as it is currently unprofitable.


Financial Health

How is Mayne Pharma Group's financial position?


Financial Position Analysis

Short Term Liabilities: MYX's short term assets (A$416.5M) exceed its short term liabilities (A$222.5M).

Long Term Liabilities: MYX's short term assets (A$416.5M) do not cover its long term liabilities (A$469.1M).


Debt to Equity History and Analysis

Debt Level: MYX's debt to equity ratio (43.8%) is considered high.

Reducing Debt: MYX's debt to equity ratio has increased from 20.3% to 43.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable MYX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: MYX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 41.4% per year.


Dividend

What is Mayne Pharma Group current dividend yield, its reliability and sustainability?

0.25%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MYX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: MYX is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Scott Richards (57 yo)

9.67yrs

Tenure

AU$3,139,294

Compensation

Mr. Scott Anthony Richards has been the Chief Executive Officer and Managing Director of Mayne Pharma Group Limited since February 13, 2012. Mr. Richards joined Mayne Pharma in February 2012. He served as...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD2.35M) is above average for companies of similar size in the Australian market ($USD723.99K).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MYX's management team is considered experienced (3.9 years average tenure).


Board Members

Experienced Board: MYX's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MYX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.1%.


Top Shareholders

Company Information

Mayne Pharma Group Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Mayne Pharma Group Limited
  • Ticker: MYX
  • Exchange: ASX
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$582.397m
  • Shares outstanding: 1.76b
  • Website: https://www.maynepharma.com

Number of Employees


Location

  • Mayne Pharma Group Limited
  • 1538 Main North Road
  • Salisbury South
  • South Australia
  • 5106
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 16:22
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.